Posted on 11 February 2010
Tags: big pharma, Daiichi Sankyo, Eli Lilly
Additionally, the companies have agreed to promote prasugrel, an anti-platelet co-developed by Daiichi Sankyo and Eli Lilly and Company, in Mexico. Prasugrel will be co-promoted by Lilly's affiliate in Mexico.
Click here to cancel reply.
Email (will not be published) (required)
Your website (optional)
© 2020 Wildwood Ventures Ltd.